Akili to Combine with Virtual Therapeutics in Go-Private Merger

Dow Jones05-29

By Adriano Marchese

Akili and Virtual Therapeutics have agreed to merge in a go-private deal that will create a larger diversified digital health company.

Shareholders of Akili, a digital therapeutics company, will receive 43.4 cents per share of common stock in cash according to the terms of the deal, the companies said Wednesday.

Akili shares have been under pressure in 2024, falling about 14% and closing at 42 cents on Tuesday. Over the last 12 months, shares are down 66%. On Wednesday, the shares were halted in premarket trading.

In a joint-statement, the two companies said that the price represents a 4% premium to Akili's closing stock price on Tuesday and about an 85% premium to the closing price on April 29, the last trading day before Akili's said it was considering potential strategic alternatives.

Akili Chief Executive Matt Franklin said that the combination of Akili's mobile digital therapeutics with Virtual Therapeutics' portfolio of virtual reality-based mental health solutions and gaming expertise, will produce a platform better able to address mental health needs across several high-impact indications.

The transaction is expected to close in the third quarter of this year.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

May 29, 2024 08:31 ET (12:31 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2439352624?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-29 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2439352624","market":"sh","top_or_hot":-1,"title":"Akili to Combine with Virtual Therapeutics in Go-Private Merger","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  Akili and Virtual <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> have agreed to merge in a go-private deal that will create a larger diversified digital health company. \n</p>\n<p>\n  Shareholders of Akili, a digital therapeutics company, will receive 43.4 cents per share of common stock in cash according to the terms of the deal, the companies said Wednesday. \n</p>\n<p>\n  Akili shares have been under pressure in 2024, falling about 14% and closing at 42 cents on Tuesday. Over the last 12 months, shares are down 66%. On Wednesday, the shares were halted in premarket trading. \n</p>\n<p>\n  In a joint-statement, the two companies said that the price represents a 4% premium to Akili's closing stock price on Tuesday and about an 85% premium to the closing price on April 29, the last trading day before Akili's said it was considering potential strategic alternatives. \n</p>\n<p>\n  Akili Chief Executive Matt Franklin said that the combination of Akili's mobile digital therapeutics with Virtual Therapeutics' portfolio of virtual reality-based mental health solutions and gaming expertise, will produce a platform better able to address mental health needs across several high-impact indications. \n</p>\n<p>\n  The transaction is expected to close in the third quarter of this year. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 29, 2024 08:31 ET (12:31 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akili to Combine with Virtual Therapeutics in Go-Private Merger</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkili to Combine with Virtual Therapeutics in Go-Private Merger\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-29 20:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Adriano Marchese \n\n\n \n\n\n  Akili and Virtual Therapeutics have agreed to merge in a go-private deal that will create a larger diversified digital health company. \n\n\n  Shareholders of Akili, a ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AKLI","symbol_name":"Akili, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2439352624","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2439352624","pubTimestamp":1716985860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Akili and Virtual Therapeutics have agreed to merge in a go-private deal that will create a larger diversified digital health company.Shareholders of Akili, a digital therapeutics company, will receive 43.4 cents per share of common stock in cash according to the terms of the deal, the companies said Wednesday.Akili shares have been under pressure in 2024, falling about 14% and closing at 42 cents on Tuesday. Over the last 12 months, shares are down 66%. On Wednesday, the shares were halted in premarket trading.In a joint-statement, the two companies said that the price represents a 4% premium to Akili's closing stock price on Tuesday and about an 85% premium to the closing price on April 29, the last trading day before Akili's said it was considering potential strategic alternatives.Akili Chief Executive Matt Franklin said that the combination of Akili's mobile digital therapeutics with Virtual Therapeutics' portfolio of virtual reality-based mental health solutions and gaming experti","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AKLI":"Akili, Inc.","BK4167":"医疗保健技术","BK4139":"生物科技","LENZ":"Therapeutics"},"translate_title":"Akili将在私有化合并中与虚拟疗法相结合","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"AKLI":0.9},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Akili and Virtual Therapeutics have agreed to merge in a go-private deal that will create a larger diversified digital health company. \n\n\n  Shareholders of Akili, a digital therapeutics company, will receive 43.4 cents per share of common stock in cash according to the terms of the deal, the companies said Wednesday. \n\n\n  Akili shares have been under pressure in 2024, falling about 14% and closing at 42 cents on Tuesday. Over the last 12 months, shares are down 66%. On Wednesday, the shares were halted in premarket trading. \n\n\n  In a joint-statement, the two companies said that the price represents a 4% premium to Akili's closing stock price on Tuesday and about an 85% premium to the closing price on April 29, the last trading day before Akili's said it was considering potential strategic alternatives. \n\n\n  Akili Chief Executive Matt Franklin said that the combination of Akili's mobile digital therapeutics with Virtual Therapeutics' portfolio of virtual reality-based mental health solutions and gaming expertise, will produce a platform better able to address mental health needs across several high-impact indications. \n\n\n  The transaction is expected to close in the third quarter of this year. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 29, 2024 08:31 ET (12:31 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2439352624"}